Trial Profile
Potential of immunotherapy to convert a complete cytogenetic remission in chronic myelogenous leukemia to a molecular complete remission: randomized phase II study of proteinase 3 PR1 peptide mixed with montanide ISA-51 VG adjuvant and administered with GM-CSF [granulocyte macrophage colony-stimulating factors] and peginterferon alfa-2b [PEG-INTRON, Schering Corporation].
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs PR1 peptide vaccine (Primary) ; Imatinib; Peginterferon alfa-2b; Sargramostim
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 09 Oct 2013 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center.
- 25 Mar 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 23 Mar 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.